Key Takeaway
Semaglutide remains the most clinically studied GLP-1 receptor agonist for weight loss, delivering average body weight reductions of 15 to 17% in...
Semaglutide remains the most clinically studied GLP-1 receptor agonist for weight loss, delivering average body weight reductions of 15 to 17% in clinical trials. But tirzepatide, liraglutide, and other alternatives each offer distinct advantages depending on your health profile, budget, and treatment goals.
Key Takeaways
- Semaglutide (Wegovy/Ozempic) produces average weight loss of 14.9 to 16.9% of body weight in important clinical trials.
- Tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP receptors, showing up to 22.5% weight[1] loss in the SURMOUNT-1 trial[1].
- Liraglutide (Saxenda) was the first FDA-approved GLP-1 for weight management but produces more modest results (about 8% weight loss).
- Compounded semaglutide offers a more affordable option for many patients and is available through physician-supervised programs like FormBlends.
- The best medication for you depends on your medical history, weight loss goals, side effect tolerance, and budget.
- All GLP-1 medications work best when combined with dietary changes and regular physical activity.
How the GLP-1 Medication space in 2026
The weight management medication space has transformed dramatically since semaglutide first received FDA approval for chronic weight management in 2021. Today, patients have more options than ever, each with different mechanisms, efficacy profiles, and price points. For a complete cost breakdown, see our cheapest semaglutide options.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
We're going to walk you through every major option, compare them head-to-head, and help you understand which one might be the best fit for your situation. This isn't a ranking. Different medications work better for different people, and the "best" option is the one that aligns with your specific needs.
How GLP-1 Medications Work
All GLP-1 receptor agonists share a core mechanism: they mimic the incretin hormone GLP-1, which your gut naturally produces after eating. This hormone signals the brain to reduce hunger, slows gastric emptying so food stays in your stomach longer, and improves insulin sensitivity .
The differences between medications come down to their receptor targets (some hit additional receptors beyond GLP-1), their half-life (how long they stay active in your body), and their dosing schedules.
Semaglutide: The Current Standard
Semaglutide is available under several brand names depending on its indication and formulation:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- Wegovy (semaglutide 2.4 mg) is FDA-approved specifically for chronic weight management.
- Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg) is FDA-approved for type 2 diabetes and is widely prescribed off-label for weight loss.
- Rybelsus (oral semaglutide) is a pill form approved for type 2 diabetes.
Clinical Efficacy
Semaglutide's weight loss credentials are backed by the extensive STEP trial program:
| Trial | Population | Average Weight Loss | Duration |
|---|---|---|---|
| STEP 1[2] | Adults with obesity (no diabetes) | 14.9% | 68 weeks |
| STEP 2 | Adults with obesity and type 2 diabetes | 9.6% | 68 weeks |
| STEP 3 | Adults with obesity + intensive behavioral therapy | 16.0% | 68 weeks |
| STEP 5 | Adults with obesity (long-term) | 15.2% | 104 weeks |
| STEP 8[6] | Head-to-head vs liraglutide | 15.8% (vs 6.4% liraglutide) | 68 weeks |
Beyond Weight Loss: Cardiovascular Benefits
The SELECT trial[7] demonstrated that semaglutide reduces major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in adults with established cardiovascular disease and overweight or obesity, regardless of diabetes status . This cardiovascular benefit sets semaglutide apart from older weight loss medications.
Side Effects Profile
The most common side effects of semaglutide are gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%). These effects are typically mild to moderate, peak during dose escalation, and improve over time . Serious but rare risks include pancreatitis, gallbladder disease, and a theoretical risk of medullary thyroid carcinoma (observed in rodent studies but not confirmed in humans).
Tirzepatide: The Dual-Action Competitor
Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight management) is a dual GIP/GLP-1 receptor agonist. By targeting two incretin receptors instead of one, it may produce greater metabolic effects than semaglutide alone .
Clinical Efficacy
| Trial | Dose | Average Weight Loss | Duration |
|---|---|---|---|
| SURMOUNT-1 | 5 mg | 15.0% | 72 weeks |
| SURMOUNT-1 | 10 mg | 19.5% | 72 weeks |
| SURMOUNT-1 | 15 mg | 20.9% | 72 weeks |
| SURMOUNT-2[8] (with T2D) | 15 mg | 14.7% | 72 weeks |
| SURMOUNT-4[9] (maintenance) | 10 or 15 mg | Maintained 21.4% at 88 weeks | 88 weeks |
Tirzepatide vs Semaglutide: Head-to-Head
The SURPASS-2 trial[10] compared tirzepatide to semaglutide 1 mg in patients with type 2 diabetes. Tirzepatide at all three doses (5, 10, and 15 mg) produced greater reductions in both HbA1c and body weight compared to semaglutide 1 mg .
But this comparison used semaglutide at 1 mg (its diabetes dose), not the 2.4 mg weight management dose. A direct comparison between tirzepatide 15 mg and semaglutide 2.4 mg hasn't yet been completed, though the SURMOUNT-5 trial is expected to provide those results.
Side Effects
Tirzepatide's side effect profile is similar to semaglutide: nausea (up to 33%), diarrhea (up to 23%), vomiting (up to 12.2%), and constipation (up to 11.7%) . Some patients who don't tolerate one GLP-1 medication may tolerate the other, as individual responses vary.
Liraglutide: The First-Generation Option
Liraglutide (Saxenda for weight management, Victoza for diabetes) was the first GLP-1 receptor agonist approved for chronic weight management in 2014. It requires daily injections, which is a notable difference from the weekly dosing of semaglutide and tirzepatide.
Clinical Efficacy
The SCALE trials showed liraglutide 3.0 mg produced average weight loss of 8.0% of body weight over 56 weeks, compared to 2.6% with placebo .
When compared directly to semaglutide in the STEP 8 trial, liraglutide's results were significantly less impressive: participants on semaglutide lost 15.8% of body weight versus 6.4% on liraglutide over 68 weeks .
When Liraglutide Might Still Make Sense
Despite being less effective for weight loss, liraglutide has some specific advantages:
- Longer safety track record (over 10 years of clinical use)
- FDA-approved for adolescents aged 12 and older
- Daily dosing allows for faster dose adjustments if side effects occur
- Some patients who can't tolerate semaglutide do well on liraglutide
thorough Comparison Table
| Feature | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Liraglutide (Saxenda) |
|---|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist | GLP-1 receptor agonist |
| Dosing | Weekly injection | Weekly injection | Daily injection |
| Max weight loss dose | 2.4 mg weekly | 15 mg weekly | 3.0 mg daily |
| Average weight loss | 14.9 to 16.0% | 15.0 to 20.9% | 6.4 to 8.0% |
| CV outcome benefit | Yes (SELECT trial) | Under investigation | Neutral |
| FDA weight mgmt approval | Yes (2021) | Yes (2023) | Yes (2014) |
| Adolescent approval | Yes (12+) | No | Yes (12+) |
| List price (monthly) | ~$1,350 | ~$1,060 | ~$1,350 |
| Compounded available | Yes | Limited | No |
| Oral formulation | Yes (Rybelsus, diabetes only) | In development | No |
Other Weight Management Alternatives
Orlistat (Xenical/Alli)
Orlistat works entirely differently from GLP-1 medications. It blocks fat absorption in the gut by inhibiting pancreatic lipase. Available by prescription (Xenical 120 mg) and over the counter (Alli 60 mg), it produces modest weight loss of 5 to 7% over 12 months .
The main drawbacks are GI side effects (oily stools, flatulence, fecal urgency) that can be socially uncomfortable, and the fact that it only works on dietary fat. It doesn't reduce appetite or address the behavioral drivers of overeating.
Phentermine-Topiramate (Qsymia)
Qsymia combines phentermine (an appetite suppressant) with topiramate (an anticonvulsant that reduces appetite through a different mechanism). It produces average weight loss of 9 to 10% over one year .
Limitations include stimulant-related side effects (increased heart rate, insomnia), potential for cognitive impairment from topiramate, teratogenicity (birth defects), and it's classified as a Schedule IV controlled substance due to the phentermine component.
Naltrexone-Bupropion (Contrave)
Contrave combines naltrexone (an opioid antagonist) with bupropion (an antidepressant). It targets the reward centers of the brain to reduce food cravings and produces average weight loss of 5 to 8% .
It may be a good option for patients with concurrent depression or those who can't use GLP-1 medications. It shouldn't be used by patients with uncontrolled hypertension, seizure disorders, or opioid use.
Peptide Therapies
Beyond traditional GLP-1 medications, peptide wellness therapy options are gaining attention for their potential to support weight management, recovery, and overall metabolic health. These therapies can complement GLP-1 treatment or serve as standalone options depending on your goals.
The Pipeline: What Is Coming Next
Several next-generation medications are in late-stage development as of 2026:
- Retatrutide: A triple agonist (GLP-1, GIP, and glucagon receptors) that showed up to 24.2% weight loss in phase 2 trials .
- Orforglipron: An oral, non-peptide GLP-1 receptor agonist in pill form that could eliminate the need for injections entirely.
- Amycretin: A dual GLP-1/amylin agonist from Novo Nordisk showing promising early results exceeding semaglutide's efficacy.
- Survodutide: A dual GLP-1/glucagon agonist being developed for obesity and metabolic liver disease.
How to Choose the Right Medication
Selecting the right weight management medication is a decision that should be made with a qualified healthcare provider. Here are the factors that matter most:
Consider Your Primary Goal
- Maximum weight loss: Tirzepatide at higher doses currently produces the greatest average weight loss in clinical trials.
- Cardiovascular protection: Semaglutide has the strongest evidence for cardiovascular risk reduction (SELECT trial).
- Blood sugar control with weight loss: Both semaglutide and tirzepatide are excellent choices for patients with type 2 diabetes.
- Budget-conscious treatment: Compounded semaglutide through programs like FormBlends offers significant cost savings while maintaining physician oversight.
Consider Your Medical History
| If You Have... | Consider | Avoid or Use Caution |
|---|---|---|
| Type 2 diabetes | Semaglutide or tirzepatide | Monitor for hypoglycemia if on sulfonylureas or insulin |
| Cardiovascular disease | Semaglutide (proven CV benefit) | Phentermine-containing medications |
| History of pancreatitis | Non-GLP-1 alternatives | All GLP-1 receptor agonists |
| Personal/family history of MTC | Non-GLP-1 alternatives | All GLP-1 receptor agonists |
| Seizure disorder | GLP-1 medications | Contrave (contains bupropion) |
| Depression | Contrave (contains bupropion, an antidepressant) | Monitor all medications for mood changes |
| Severe GI conditions | Non-GLP-1 alternatives | GLP-1 medications may worsen gastroparesis |
Consider Cost and Access
Brand-name GLP-1 medications carry significant costs, often exceeding $1,000 per month without insurance coverage. Many insurance plans still don't cover weight management medications, creating a substantial barrier to access.
This is one reason compounded versions of semaglutide have become popular. Through physician-supervised telehealth programs, patients can access semaglutide at a fraction of the brand-name price while still receiving proper medical oversight, dose management, and support.
Consider Your Lifestyle
- Weekly vs daily injections: If the idea of daily injections is a dealbreaker, semaglutide and tirzepatide offer weekly dosing convenience.
- Needle-free options: Oral semaglutide (Rybelsus) exists but is currently only approved for diabetes and produces less weight loss than the injectable form.
- Travel and storage: All injectable GLP-1 medications require refrigeration until first use. Consider your travel schedule and storage options.
Switching Between Medications
It isn't uncommon for patients to switch from one GLP-1 medication to another. Common reasons include:
- Inadequate weight loss response to the first medication
- Intolerable side effects that don't improve with time
- Insurance coverage changes
- Desire for greater efficacy after reaching a plateau
If you're considering a switch, work closely with your provider. The transition typically involves stopping one medication and starting the new one at its lowest dose, with gradual escalation. Don't attempt to switch medications on your own or take two GLP-1 medications simultaneously.
Why Semaglutide Remains a Top Choice in 2026
Despite newer options entering the market, semaglutide continues to be the most widely prescribed GLP-1 for weight management, and for good reason:
- Proven cardiovascular benefits. The SELECT trial data gives semaglutide a unique advantage for patients with cardiovascular risk.
- Extensive safety data. With years of real-world use across millions of patients, its safety profile is well characterized.
- Availability and access. Compounded semaglutide provides more affordable access than most alternatives.
- Strong efficacy. While tirzepatide may produce greater average weight loss at the highest doses, semaglutide's results are still among the most impressive in obesity medicine history.
- Strong clinical trial program. The STEP trial series provides evidence across diverse patient populations.
For many patients, semaglutide offers the best combination of proven efficacy, safety data, and accessibility. Through FormBlends, you can access physician-supervised semaglutide for beginners treatment with the support you need to achieve lasting results.
Frequently Asked Questions
Is tirzepatide better than semaglutide for weight loss?
Tirzepatide at its highest dose (15 mg) has shown greater average weight loss than semaglutide 2.4 mg in separate clinical trials (about 21% vs 15%). But a direct head-to-head comparison at full weight loss doses hasn't been published yet. Both medications produce clinically significant weight loss, and individual responses vary. Some patients respond better to semaglutide than tirzepatide and vice versa.
Can I switch from Ozempic to Wegovy?
Yes. Ozempic and Wegovy both contain semaglutide. The main difference is dosing: Wegovy goes up to 2.4 mg for weight management, while Ozempic maxes out at 2 mg for diabetes. Your provider can guide you through the transition, which is generally straightforward since it's compounded formulations of the active ingredient.
Why is semaglutide so expensive?
Brand-name semaglutide (Wegovy/Ozempic) is priced at over $1,000 per month largely due to manufacturer pricing decisions, patent protections, and high demand. Limited insurance coverage for weight management indications makes out-of-pocket costs even higher. Compounded semaglutide through physician-supervised programs like FormBlends offers a more affordable path to treatment.
What is the difference between compounded and brand-name semaglutide?
Compounded semaglutide contains compounded formulations of the active ingredient as brand-name versions but is prepared by licensed compounding pharmacies. It's available when brand-name versions face shortages or when patients can't access the branded products. It's typically much more affordable. The key is ensuring your compounded medication comes from a reputable, licensed pharmacy with proper physician oversight.
Are there any weight loss pills that work as well as semaglutide injections?
No currently available oral medication matches injectable semaglutide's weight loss efficacy. Oral semaglutide (Rybelsus) produces less weight loss than the injectable form due to lower bioavailability. But orforglipron, an oral non-peptide GLP-1 agonist in clinical trials, could potentially change this. For now, injectable GLP-1 medications remain the most effective pharmaceutical options.
Can I take semaglutide with other weight loss medications?
Combining multiple GLP-1 receptor agonists isn't recommended. But your physician may consider adding certain non-GLP-1 medications in specific situations. Never combine weight loss medications on your own. Always discuss combination therapy with your provider.
How long do I need to take semaglutide?
Current evidence suggests that semaglutide works best as a long-term treatment. The STEP 1 extension study showed that patients who stopped semaglutide regained about two-thirds of their lost weight within one year . Your provider will help you determine the right duration based on your individual goals and response.
Medical References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2023;327(2):138-150. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. [PubMed | ClinicalTrials.gov | DOI]
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. [PubMed | DOI]
Find Your Best Option with Expert Guidance
Choosing between semaglutide and its alternatives isn't a decision you should make based on an article alone. At FormBlends, our physicians evaluate your complete health profile, discuss your goals, and recommend the medication that gives you the best chance of lasting success. Start your consultation today and get a personalized treatment plan built around your needs.